Sight Sciences, Inc. (SGHT)

Market Cap	161.83M
Revenue (ttm)	78.11M
Net Income (ttm)	-49.40M
Shares Out	51.70M
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	302,879
Open	3.280
Previous Close	3.080
Day's Range	3.060 - 3.390
52-Week Range	2.030 - 8.450
Beta	2.40
Analysts	Buy
Price Target	3.92 (+25.24%)
Earnings Date	May 8, 2025

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 216
• Stock Exchange: NASDAQ
• Ticker Symbol: SGHT
• Website: https://www.sightsciences.com

Financial Performance

In 2024, Sight Sciences's revenue was $79.87 million, a decrease of -1.47% compared to the previous year's $81.06 million. Losses were -$51.51 million, -7.27% less than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price forecast is $3.92, which is an increase of 25.24% from the latest price.

Price Target

$3.92

(25.24% upside)

Analyst Consensus: Buy